Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bystander effect of vinorelbine alters antitumor immune response.
Thomas-Schoemann A, Lemare F, Mongaret C, Bermudez E, Chéreau C, Nicco C, Dauphin A, Weill B, Goldwasser F, Batteux F, Alexandre J. Thomas-Schoemann A, et al. Int J Cancer. 2011 Sep 15;129(6):1511-8. doi: 10.1002/ijc.25813. Epub 2011 Apr 1. Int J Cancer. 2011. PMID: 21128224
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B. Boudou-Rouquette P, et al. PLoS One. 2012;7(8):e42875. doi: 10.1371/journal.pone.0042875. Epub 2012 Aug 13. PLoS One. 2012. PMID: 22912756 Free PMC article.
Drug interactions with solid tumour-targeted therapies.
Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F. Thomas-Schoemann A, et al. Crit Rev Oncol Hematol. 2014 Jan;89(1):179-96. doi: 10.1016/j.critrevonc.2013.08.007. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24041628 Review.
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F. Huillard O, et al. Expert Opin Drug Saf. 2014 May;13(5):663-73. doi: 10.1517/14740338.2014.907270. Epub 2014 Apr 3. Expert Opin Drug Saf. 2014. PMID: 24693873 Review.
Sorafenib in thyroid cancer patients: learning from toxicity.
Huillard O, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A, Wassermann J, Goldwasser F. Huillard O, et al. Oncologist. 2014 Aug;19(8):e3. doi: 10.1634/theoncologist.2014-0156. Epub 2014 Jul 22. Oncologist. 2014. PMID: 25052452 Free PMC article.
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M, Tod M, Alexandre J, Loriot MA, Goldwasser F, Blanchet B. Narjoz C, et al. Invest New Drugs. 2015 Feb;33(1):257-68. doi: 10.1007/s10637-014-0178-2. Epub 2014 Oct 25. Invest New Drugs. 2015. PMID: 25344452 Clinical Trial.
52 results